Fibrillazione atriale subclinica e rischio di ictus ischemico
|
|
|
- Jayson Sims
- 5 years ago
- Views:
Transcription
1 Fibrillazione atriale subclinica e rischio di ictus ischemico
2 Background 25% of all ischemic strokes are cryptogenic, and subclinical atrial fibrilla;on (AF) is suspected to be a possible cause in many of these. The prevalence and prognosis of subclinical AF has been difficult to assess. Cardiac Implantable Electronic Devices (CIEDs) have the capacity to record episodes of atrial tachyarrhythmia. The significance and management strategies of devicedetected subclinical AF are not clearly defined.
3 As Cardiac Monitoring Evolves, Diagnos=c Yield Improves 88% Rela=ve diagnos=c yield ECG symptom correlation 5% 13% Holter Monitor 15% Event Monitor: Non-looping Syncope 6% 25% Palpitations 39% 68% Event Monitor: Looping Memory 36% AF Auto-trigger Monitor 45% 88% Invasive Implantable Loop Recorder CardioNet MCOT (Mobile Cardiac Outpatient Telemetry) The technology available for arrhythmia monitoring has evolved since the Holter monitor was first developed in the late 1940s. The diagnos;c yield of these methods has increased substan;ally over ;me: MCOT is the latest milestone on the road to beaer arrhythmia diagnosis and management. References: Assar MD et al. Am J Cardiol. 2003;92: Fechter P. Schweiz Med Wochenschr. 1991;121: Fogel RI et al. Am J Cardiol. 1997;79: Gibson TC et al. Am J Cardiol. 1984;53: Kinlay S et al. Ann Intern Med. 1996;124: Krahn AD et al. Circula9on. 2001;104: Krahn AD et al. PACE. 2004;27: Linzer M et al. Am J Cardiol. 1990;66: Reiffel JA et al. Am J Cardiol. 2005;95: Rothman SA et al. J Cardiovasc Electrophysiol. 2007;18: Zeldis SM et al. Chest. 1980;78: Zimetbaum P et al. Am J Cardiol. 1997;79:371-2.
4 Atrial High Rate Episodes (AHRE)
5 Incidence of CIEDs-detected AHREs in pa=ents with risk factors for stroke Study ASSERT II, 2016 REVEAL-AF, 2017 Pa=ents characteris=cs > 65 years, CHA2DS2-VASc > 2 or OSA or BMI > 30, with enlarged lee atrium or NT-proBNP > 290 pg/ml CHADS2 > 3 or =2 addi;onal risk factors (OSA, CAD, COPD or GFR ml/min) AHRE burden threshold AF > 5 min AF > 6 min Incidence of AHRE (%) 34.4 at 12 months 20.4 at 12 months PREDATE-AF, 2017 CHA2DS2-VASc > 2 AF > 6 min 22.4 at 451 days
6 Rela=onship between AF burden and stroke Author No. of pa=ents AF burden associated with stroke HR (95%, CI) Glotzer, with SSS > 5 min 2,79 ( ) Capucci, with bradyarrhythmias > 24 h 3.1 ( ) Glotzer, with PM or AICD > 5.5 h 2.2 ( ) Healey, , no history of PAF > 6 min 2.49 ( ) Shanmugan, with CRT > 3.8 h 9.4 ( ) Boriani, with a CIED > 1 h 2.11 ( ) Van Gelder, , no history of PAF > 24 h 3.24 ( )
7 Rela=onship between AF and tromboembolic events in pa=ents with CIEDs Autors No. of TE events AF before TE (%) AF in the 30 days before TE (%) AF at the =me of TE events (%) AF only aser TE events (%) Daoud, Boriani, NA Shanmugan, NA 27 NA BrambaU, Mar9n, NA 7
8 Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
9 Methods Search strategy The English scien;fic literature was searched using Pubmed and Embase with keywords ( subclinical OR device-detected ) AND atrial fibrilla;on AND ( pacemaker OR Implantable Cardioverter Defibrillator OR Cardiac Resynchroniza;on Therapy Device OR CIED) up to 1 April Inclusion and exclusion criteria The ar=cles of interest were those describing the associa=on of device-detected subclinical AF and stroke in pa=ents with CIEDs with implanted atrial leads. The exclusion criteria were: (i) intermiaent monitoring for AF detec;on; (ii) conference abstracts, editorials, reviews, leaers, and case reports; (iii) reviews were excluded but their reference lists hand searched for poten;al relevant publica;ons; (iv) case series with less than 50 pa;ents. Where mul;ple studies described the same popula;on (substudies, follow-up studies), the study with the most comprehensive data was included. Study selec=on and data extrac=on The study selec;on and data extrac;on were performed by the authors using a priori determined criteria. The methodological quali;es of the included studies were assessed using the modified Newcastle- Oaawa Scale. The outcomes of the analysis were defined as: (i) defini;on of subclinical AF in different studies and cutoff for recognizing subclinical AF; (ii) prevalence of subclinical AF; (iii) associa;on of subclinical and clinical AF; (iv) associa;on of subclinical AF and stroke risk; and (v) temporal rela;onship of subclinical AF and stroke in pa;ents with CIEDs. From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
10 Results Search and synthesis of the literature From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
11 Criteria and cut-off for detec=on of subclinical AF Criteria for AHRE Minimum cut-off to recognise subclinical AF Dura=on of subclinical AF assessed for stroke risk From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
12 Study design and defini=on of subclinical AF in the included studies Study Study design Sample size Follow up AF at =me of enrollment Cut-off for AF/AHRE detec=on and dura=on associated with stroke risk From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis. Eur Heart J. 2018;39(16): doi: /eurheartj ehx731
13 Associa=on between subclinical and clinical AF Associa=on between subclinical AF and stroke risk From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
14 Temporal associa=on between subclinical AF and stroke Studies Total strokes AHRE absent AHRE present From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis. Eur Heart J. 2018;39(16): doi: /eurheartj ehx731
15 Key-messages Subclinical AF is highly prevalent in pa;ents with CIEDs and predicts clinical AF. From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
16 Key-messages Subclinical AF was associated with a 2.4-fold increase in stroke risk. However, the overall absolute annual risk of stroke was 1.89 per 100 person-years. For studies that provided CHADS 2 score, the absolute annual stroke risk is higher at 2.76 per 100 person-years for a mean CHADS 2 score of 2.1. From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
17 Key-messages Short episodes of subclinical AF (<described cut-off) were uniformly associated with low risk of stroke (0.93 per 100 person-years). Although temporal dissocia;on of subclinical AF and stroke is reported, the studies have certain biases. From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
18 Conclusions Subclinical AF is frequent in pa;ents with CIEDs and is strongly associated with clinical AF. The stroke risk with subclinical AF is low as compared to clinical AF and could poten;ally represent smaller burden. Further research is required to define the role of AF burden in stroke risk. From: Subclinical device-detected atrial fibrilla;on and stroke risk: a systema;c review and meta-analysis Eur Heart J. 2018;39(16): doi: /eurheartj/ehx731
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January
SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!!
SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!! Atrial tachycardia «ATRIAL HIGH RATES EPISODES» (AHREs) Episodes
Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY Turin October 13-15, 2016 Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients Dott.
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study Taya V. Glotzer, MD; Emile G. Daoud, MD; D. George Wyse, MD, PhD; Daniel
Subclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
Causal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
Defining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
Diagnosing atrial fibrillation using implantable devices
Diagnosing atrial fibrillation using implantable devices Axel Brandes, MD, FESC Associate Professor of Electrophysiology and Cardiac Arrhythmias Dept. of Cardiology, Odense University Hospital, DK HRC
Causal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
Atrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment
MAEDICA a Journal of Clinical Medicine 2018; 13(4): 261-265 https://doi.org/10.26574/maedica.2018.13.4.261 Mædica - a Journal of Clinical Medicine Invited Editorial Point of View Subclinical Atrial Fibrillation,
Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation
48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December
ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ
ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ 9 Ο Βορειοελλα ATRIAL FIBRILATION Atrial fibrillation (AF) is the most common clinically significant heart
Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia
Gianluca Botto, FESC Elettrofisiologia Ospedale Sant Anna, Como Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia 20 min Presenter Disclosure Information n n n Research
La strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole
La strategia diagnostica: il monitoraggio ecg prolungato Michele Brignole ECG monitoring and syncope In-hospital monitoring Holter Monitoring External loop recorder Remote (at home) telemetry Implantable
Consensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
Cryptogenic Stroke: The role of silent Atrial Fibrillation
Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a
Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;
Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο
Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici?
Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici? Fabrizio Ammirati Dipartimento Medicina UOC Cardiologia Ospedale GB Grassi ASL Roma 3 Sept 2013 Patients
Device Diagnostics and Stroke Prevention: State of the Art
Device Diagnostics and Stroke Prevention: State of the Art Ass. Prof. Dr. Carsten W. Israel Dept. of Cardiology Evangelical Hospital Bielefeld Germany C.W.Israel@em.uni-frankfurt.de Disclosure of Relationships
Ambulatory Cardiac Monitors and Outpatient Telemetry Corporate Medical Policy
Ambulatory Cardiac Monitors and Outpatient Telemetry Corporate Medical Policy File Name: Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry File Code: UM.SPSVC.13 Origination: 10/2015 Last
AF Detection During Drug Development: What Constitutes a Signal
AF Detection During Drug Development: What Constitutes a Signal Peter R. Kowey, FACC, FAHA, FHRS Lankenau Heart Institute Jefferson Medical College Philadelphia, PA Disclosure Dr. Kowey has consulted for
Στυλιανός Τζέης MD, PhD, FESC
Βραχειάς δια ρκειας ριπε ςυπερκοιλιακη ς ταχυαρρυθμιάς στο Holter ρυθμου η στις συσκευε ςδιαχει ρισης του καρδιακου ρυθμου. Θα χορηγη σουμε αντιθρομβωτικη αγωγη ; Στυλιανός Τζέης MD, PhD, FESC Επιμελητής
CASE STUDY: THE CLINICAL BENEFIT OF MOBILE CARDIAC OUTPATIENT TELEMETRY. June 22, 2009
CASE STUDY: THE CLINICAL BENEFIT OF MOBILE CARDIAC OUTPATIENT TELEMETRY June 22, 2009 Sanjeev Wasson, MD, FACC, Medical Director, Department of Electrophysiology Skagit Valley Medical Center and Skagit
Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?
Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Helmut Pürerfellner, MD, Assoc. Prof. Saint Elisabeth s Sisters Hospital Academic Teaching Center Linz/Austria
Asymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco
Asymptomatic Atrial Fibrillation: Detection and Management 18 December 2015 32 nd Annual Advances in Heart Disease Palace Hotel, San Francisco Zian H. Tseng, M.D., M.A.S. Associate Professor of Medicine
UTILITY OF THE IMPLANTABLE LOOP RECORDER
UTILITY OF THE IMPLANTABLE LOOP RECORDER John Andriulli, DO Associate Professor of Medicine Director, Arrhythmia Device Program Cooper Medical School of Rowan University Contemporary Practices in Cardiology
Topic: Outpatient Cardiac Telemetry Date of Origin: April Section: Medicine Last Reviewed Date: December 2014
Medical Policy Manual Topic: Outpatient Cardiac Telemetry Date of Origin: April 2010 Section: Medicine Last Reviewed Date: December 2014 Policy No: 135 Effective Date: February 1, 2014 IMPORTANT REMINDER
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention
Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention Data that date back to the 1970 s have illustrated the strong relationship between atrial fibrillation
AF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
Device detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
Medicare Advantage Medical Policy
Medicare Advantage Medical Policy Current Policy Effective Date: 1/1/18 Title: Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Description/Background Indications for Ambulatory Cardiac
MEDICAL POLICY Cardiac Event Monitors/ Cardiac Event Detection
POLICY: PG0039 ORIGINAL EFFECTIVE: 10/01/11 LAST REVIEW: 12/12/17 MEDICAL POLICY Cardiac Event Monitors/ Cardiac Event Detection GUIDELINES This policy does not certify benefits or authorization of benefits,
Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it?
The 12 International Dead Sea Symposium - Jerusalem March 3-5 /2014 Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? Antonio Raviele, MD, FESC, FHRS Past Director
Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring
Solomon et al. BMC Cardiovascular Disorders (2016) 16:35 DOI 10.1186/s12872-016-0210-x RESEARCH ARTICLE Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory
2009 CPT Codes for Cardiac Device Monitoring
2009 CPT Codes for Cardiac Device Monitoring December 2008 Notices Current Procedural Terminology (CPT ) is copyright 2008 American Medical Association. All Rights reserved. No fee schedules, basic units,
ATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA PATTERN
Atrial Fibrillation and Heart Failure: the ugly and the nasty 13 International Meeting February 14-15 th 2019, Bologna ATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA
POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 7/1/2002 Most Recent Review Date (Revised): 2/28/2018 Effective Date: 10/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ambulatory_event_monitors 10/2000 4/2017 4/2018 5/2017 Description of Procedure or Service There are a wide
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Policy Number: Original Effective Date: MM.02.021 02/01/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/28/2017
A Streamlined Approach to Atrial Fibrillation Screening
A Streamlined Approach to Atrial Fibrillation Screening Partnership between the Cardiac Rhythm Management Team & Department of Stroke Medicine 1 Dowds J, 1 Britton J, 1 McNair W, 1 Turkington L, 1 Curry
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic
Efstratios I. Charitos 1, Paul D. Ziegler 2, Ulrich Stierle 1, Hans-Hinrich Sievers 1, Hauke Paarmann 3, Thorsten Hanke 1. What s New?
Atrial fibrillation density 3 Applied Cardiopulmonary Pathophysiology 7: 3-0, 203 Atrial fibrillation density: A novel measure of atrial fibrillation temporal aggregation for the characterization of atrial
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ambulatory Event Monitors and Mobile
Clinical Policy Title: Implantable cardiac loop recorders
Clinical Policy Title: Implantable cardiac loop recorders Clinical Policy Number: 04.01.05 Effective Date: April 1, 2015 Initial Review Date: November 19, 2014 Most Recent Review Date: November 16, 2016
An Approach to the Patient with Syncope. Guy Amit MD, MPH Soroka University Medical Center Beer-Sheva
An Approach to the Patient with Syncope Guy Amit MD, MPH Soroka University Medical Center Beer-Sheva Case presentation A 23 y.o. man presented with 2 episodes of syncope One during exercise,one at rest
Clinical Policy Title: Implantable cardiac loop recorders
Clinical Policy Title: Implantable cardiac loop recorders Clinical Policy Number: 04.01.05 Effective Date: April 1, 2015 Initial Review Date: November 19, 2014 Most Recent Review Date: November 16, 2016
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Policy Number: 2.02.08 Last Review: 9/2018 Origination: 11/2002 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
Use of a Noninvasive Continuous Monitoring Device in the Management of Atrial Fibrillation: A Pilot Study
Use of a Noninvasive Continuous Monitoring Device in the Management of Atrial Fibrillation: A Pilot Study The Harvard community has made this article openly available. Please share how this access benefits
MEDICAL POLICY SUBJECT: AMBULATORY EVENT MONITORS
MEDICAL POLICY SUBJECT: AMBULATORY EVENT MONITORS PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
Subclinical Atrial Fibrillation and the Risk of Stroke
The new england journal of medicine original article Subclinical Atrial Fibrillation and the Risk of Stroke Jeff S. Healey, M.D., Stuart J. Connolly, M.D., Michael R. Gold, M.D., Carsten W. Israel, M.D.,
OAC after apparently successfull AF ablation: when, why, and how?
Gulf EP Live 2015 - Dubai January 22-24 / 2015 OAC after apparently successfull AF ablation: when, why, and how? Antonio Raviele, MD, FESC, FHRS Past Director Cardiovascular Department, dell Angelo Hospital,
Ictus criptogenetico: possiamo ridurre questa diagnosi?
FIBRILLAZIONE ATRIALE Ictus criptogenetico: possiamo ridurre questa diagnosi? Maurizio Landolina MD, FESC Direttore U.O.C. Cardiologia, Ospedale Maggiore di Crema Disclosures Speakers bureau appointment
Atrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands
Atrial fibrillation and stroke Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January 2018 Content Stroke what is the problem for patients with AF?
Performance of Atrial Fibrillation Detection in a New Single-Chamber ICD
DEVICES Performance of Atrial Fibrillation Detection in a New Single-Chamber ICD ABHISHEK DESHMUKH, M.D.,* MARK L. BROWN, PH.D., ELISE HIGGINS, B.S., BRIAN SCHOUSEK, B.S., ATHULA ABEYRATNE, PH.D., GIOVANNI
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
Supplemental Material
Supplemental Material 1 Table S1. Codes for Patient Selection Cohort Codes Primary PM CPT: 33206 or 33207 or 33208 (without 33225) ICD-9 proc: 37.81, 37.82, 37.83 Primary ICD Replacement PM Replacement
AF burden is important fact or fiction?
REVIEW ARTICLE AF burden is important fact or fiction? G. Boriani, I. Diemberger, M. Ziacchi, C. Valzania, B. Gardini, P. Cimaglia, C. Martignani, M. Biffi Linked Comment: Lip. Int J Clin Pract 2014; 68:
Ambulatory Cardiac Monitoring Modalities
Ambulatory Cardiac Monitoring Modalities NAVIGATING THE CHOICES MKT0390.03 LEARNING OBJECTIVES Identify the Clinical Applications for Each Modality Define and Distinguish Between the Various Monitoring
Top 5 Things to Know about Pacemakers and ICD s. Jeffrey S. Osborn, M.D., C.C.D.S. March 4, 2017.
Top 5 Things to Know about Pacemakers and ICD s Jeffrey S. Osborn, M.D., C.C.D.S. March 4, 2017. Top 5 Things 1. Remote Monitoring leads to better care and outcomes. 2. MRI s CAN be done on device patients.
Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
What s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to screen for Atrial Fibrilla7on: The REHEARSE- AF Study
Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to screen for Atrial Fibrilla7on: The REHEARSE- AF Study Julian Halcox 1,2, Kathie Wareham 1,2, Toni Cardew 1, Mark Gilmore 2,
Analyses of risk factors and prognosis for new-onset atrial fibrillation in elderly patients after dual-chamber pacemaker implantation
Journal of Geriatric Cardiology (2018) 15: 628 633 2018 JGC All rights reserved; www.jgc301.com Research Article Open Access Analyses of risk factors and prognosis for new-onset atrial fibrillation in
Why to monitor AF ablation success?
Why to monitor AF ablation success? Why to monitor AF ablation success? CASTLE-AF Primary Endpoint All-cause mortality Worsening heart failure admissions Secondary Endpoints All-cause mortality Worsening
November 2016 POWERFULLY SIMPLE CARDIAC MONITORING. SEEQ External Cardiac Monitor (ECM) System. From the leaders who brought you Reveal LINQ ICM
November 2016 POWERFULLY SIMPLE CARDIAC MONITORING SEEQ External Cardiac Monitor (ECM) System From the leaders who brought you Reveal LINQ ICM TRADITIONAL HOLTER MONITORING TYPICALLY 1-2 DAYS NOT LONG
Diagnostic capabilities of the implantable therapeutic systems
Cardiac pacing 2012 and beyound Monday August 27, 2012 Diagnostic capabilities of the implantable therapeutic systems Pekka Raatikainen Heart Center Co. Tampere University Hospital and University of Tampere
Name of Policy: Mobile Cardiac Outpatient Telemetry and Hybrid Devices
Name of Policy: Mobile Cardiac Outpatient Telemetry and Hybrid Devices Policy #: 460 Latest Review Date: March 2014 Category: Medical Policy Grade: Effective January 2, 2013, this remains an active policy
Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015
Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015 Atul Verma, MD FRCPC FHRS Director, Heart Rhythm Program Southlake Regional Health Centre Newmarket, Ontario, Canada Chair,
OUTPATIENT CARDIOVASCULAR TELEMETRY
MEDICAL POLICY OUTPATIENT CARDIOVASCULAR TELEMETRY Policy Number: 2014T0489M Effective Date: August 1, 2014 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE APPLICABLE CODES.. DESCRIPTION OF
TOP 3: EMBRACE. Lucy Vieira MD FRCP Neurologist MUHC. N Engl J Med Volume 370(26): June 26, David J.
TOP 3: EMBRACE N Engl J Med Volume 370(26):2467-2477 June 26, 2014 David J. Gladstone et al Lucy Vieira MD FRCP Neurologist MUHC Receiving research funds AstraZeneca 2014-2016 Original Article Atrial Fibrillation
Clinical Investigations
Clinical Investigations New Real-Time Loop Recorder Diagnosis of Symptomatic Arrhythmia Via Telemedicine Address for correspondence: Eran Leshem-Rubinow, MD Department of Internal Medicine E Tel Aviv Sourasky
Atrial fibrillation (AF) is the most
www.lejacq.com ID:8644 R e v i e w Pa p e r Remote Monitoring for Atrial Fibrillation Atrial fibrillation (AF) is the most common arrhythmia seen in clinical practice. In the United States, the prevalence
Fibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
US Ambulatory Electrocardiography (ECG) Market: Industry Analysis & Outlook ( )
Industry Research by Koncept Analytics US Ambulatory Electrocardiography (ECG) Market: Industry Analysis & Outlook ----------------------------------------- January 2018 US Ambulatory Electrocardiography
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
Ambulatory Event Monitors and Mobile Cardiac Page: 1 of 20 Last Review Status/Date: March 2015 Ambulatory Event Monitors and Mobile Cardiac Description There are a wide variety of devices available for
OUTPATIENT CARDIAC TELEMETRY
OUTPATIENT CARDIAC TELEMETRY UnitedHealthcare Oxford Clinical Policy Policy Number: CARDIOLOGY 017.22 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Policy Number: Original Effective Date: MM.02.021 02/01/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/27/2018
National Medical Policy
National Medical Policy Subject: Implantable Cardiac Event Monitors Policy Number: NMP495 Effective Date*: November 2009 Update: May 2016 ARCHIVE: NOTE: This policy has been retired. Please use DME Policy
PATIENT WITH ARRHYTHMIA IN DENTIST S OFFICE. Małgorzata Kurpesa, MD., PhD. Chair&Department of Cardiology
PATIENT WITH ARRHYTHMIA IN DENTIST S OFFICE Małgorzata Kurpesa, MD., PhD. Chair&Department of Cardiology Medical University of Łódź The heart is made up of four chambers Left Atrium Right Atrium Left Ventricle
Spontaneous Atrial Fibrillation and Noacs and Reversal agents
Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial
Cardiac Implanted Electronic Devices Pacemakers, Defibrillators, Cardiac Resynchronization Devices, Loop Recorders, etc.
Cardiac Implanted Electronic Devices Pacemakers, Defibrillators, Cardiac Resynchronization Devices, Loop Recorders, etc. The Miracle of Living February 21, 2018 Matthew Ostrom MD,FACC,FHRS Division of
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
Atrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Single-use Ambulatory Electrocardiographic Monitors (e.g., Zio Patch) MP-076-MD-DE Medical Management Provider Notice Date:
Cardiac Event Monitors
Last Review Date: July 14, 2017 Number: MG.MM.DM.18aCv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Defibrillation Testing should be routinely performed at the time of ICD implantation. Jeff Healey MD, MSc, FHRS McMaster University
Defibrillation Testing should be routinely performed at the time of ICD implantation Jeff Healey MD, MSc, FHRS McMaster University Presenter Disclosure Information Jeff S. Healey, MD, MSc, McMaster University,
AF monitoring and stroke: XPECT & REVEAL LINQ. Helmut Pürerfellner, Linz, Austria
AF monitoring and stroke: XPECT & REVEAL LINQ Helmut Pürerfellner, Linz, Austria 2 Medtronic Confidential 3 Circ Arrhythm Electrophysiol 2010;3:141-47 Reveal XT versus LINQ 5 Parameter Reveal XT Reveal
Clinical Policy Title: Real-time outpatient cardiac monitoring
Clinical Policy Title: Real-time outpatient cardiac monitoring Clinical Policy Number: 04.01.01 Effective Date: September 1, 2013 Initial Review Date: March 21, 2013 Most Recent Review Date: March 15,
CLINICAL SUMMARY COGENT-4 FIELD FOLLOWING STUDY
CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY COGENT-4 FIELD FOLLOWING STUDY
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
Clinical Study Predictors of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Strokes Detected by Long-Term Noninvasive Cardiac Monitoring
SAGE-Hindawi Access to Research Stroke Research and Treatment Volume 2011, Article ID 172074, 5 pages doi:10.4061/2011/172074 Clinical Study Predictors of Occult Paroxysmal Atrial Fibrillation in Strokes
Management of atrial fibrillation in heart failure
Nationale hartfalendag 2017 Zeist Management of atrial fibrillation in heart failure Isabelle C Van Gelder University of Groningen University Medical Center Groningen The Netherlands Disclosures Grant
How Wireless Remote Monitoring Improves Clinical Benefits;
How Wireless Remote Monitoring Improves Clinical Benefits; A CLINICAL CASE STUDY Suneet Mittal, M.D., The Arrhythmia Institute at Valley Hospital, Ridgewood, NJ; New York, New York; E. Martin Kloosterman,
Shock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support